University of Groningen ADPKD Casteleijn, Niek IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2017 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Casteleijn, N. (2017). ADPKD: Beyond Growth and Decline [Groningen]: Rijksuniversiteit Groningen Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 11-02-2018
ADPKD Beyond Growth and Decline Niek F. Casteleijn
Niek F. Casteleijn ADPKD - Beyond Growth and Decline The research described in this thesis is on behalf of the DIPAK Consortium and is supported by grants of the Dutch Kidney Foundation (Grants CP10.12 and CP15.01) and the Dutch Government (LSHM15018). Financial support by the University of Groningen, University Medical Center Groningen, Graduate School for Drug Exploration (GUIDE), Dutch Kidney Foundation for the publication of this thesis is gratefully acknowledged. Cover design: Alex van der Wal Illustration & lay-out: Nicole Nijhuis, Gildeprint Printed by: Gildeprint, Enschede ISBN: 978-90-367-9274-5 (printed version) ISBN: 978-90-367-9273-8 (digital version) Further financial support for the printing of this thesis was kindly provided by AbbVie B.V.; Astellas Pharma B.V.; Chipsoft B.V.; ERBE Nederland B.V.; Eurocept Homecare; Ipsen Farmaceutica B.V.; NierNieuws; Noord Negentig Accountants en Belastingadviseurs; Olympus Nederland B.V.; Otsuka Pharmaceuticals Europe Ltd.; Shire International Licensing B.V.; Thermo Fisher Scientific; Zambon Nederland B.V. N.F. Casteleijn 2016 All rights reserved. No part of this publication may be reproduced, copied, modified, stored in a retrieval system or transmitted without the prior written consent of the author.
ADPKD Beyond Growth and Decline Proefschrift ter verkrijging van de graad van doctor aan de Rijksuniversiteit Groningen op gezag van de rector magnificus prof. dr. E. Sterken en volgens besluit van het College voor Promoties. De openbare verdediging zal plaatsvinden op woensdag 11 januari 2017 om 14.30 uur door Niek Frederik Casteleijn geboren op 11 september 1989 te Wageningen
Promotores Prof. dr. R.T. Gansevoort Prof. dr. C.A.J.M. Gaillard Prof. dr. G.J. Groen Copromotor Dr. A.M. Leliveld Beoordelingscommissie Prof. dr. I.J. de Jong Prof. dr. J.P.H. Drenth Prof. dr. R. Zietse
Paranimfen Drs. J. Helfferich M.D.A. van Gastel The research described in this thesis is on behalf of the DIPAK Consortium and is supported by grants of the Dutch Kidney Foundation (Grants CP10.12 and CP15.01) and the Dutch Government (LSHM15018).
Contents 1. General introduction 9 I. Pain in ADPKD 2. The association of combined total kidney and liver volume with pain 29 and gastrointestinal symptoms in patients with later stage ADPKD 3. Management of renal cyst infection in patients with ADPKD: 49 a systematic review 4. Tolvaptan and kidney pain in patients with ADPKD: secondary analysis 67 from a randomized controlled trial 5. Chronic kidney pain in ADPKD, a case report of successful 89 treatment by catheter-based renal denervation 6. A stepwise approach for effective management of chronic pain 99 in ADPKD 7. Results of a novel treatment protocol for invalidating chronic pain 127 in patients with ADPKD II. Polyuria in ADPKD 8. Urine concentrating capacity, vasopressin and copeptin in ADPKD 153 and IgA nephropathy patients with renal impairment 9. Urine and plasma osmolality in patients with ADPKD: reliable 175 indicators of vasopressin activity and disease prognosis? 10. Polyuria due to vasopressin V2 receptor antagonism is not 193 associated with increased ureter diameter in ADPKD patients 11. General discussion and future perspectives 211 Nederlandse samenvatting 231 Dankwoord 241 About the author 247 List of publications 249